logo

Viking Therapeutics, Inc. (VKTX)



Trade VKTX now with
  Date
  Headline
9/9/2020 7:09:54 AM Viking Therapeutics Says Commences Phase 1 Trial Of VK0214 As Potential Treatment For X-linked Adrenoleukodystrophy
8/28/2020 6:09:17 AM Viking Therapeutics Presents New Data From Phase 2 Study Of VK2809 In Patients With NAFLD And Elevated LDL-Cholesterol
8/20/2020 7:39:54 AM Viking To Present Data From Phase2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease&Elevated LDL-C
11/19/2019 7:14:37 AM Viking Therapeutics Begins Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH
11/5/2019 7:24:46 AM Viking Therapeutics Q3 Net Loss Of $5.7 Mln Or $0.08/shr Vs. Net Loss Of $6.6 Mln Or $0.11/shr Prior Year
7/2/2019 4:06:23 PM Viking Therapeutics Appoints Kathy Rouan To Board Of Directors
5/2/2019 4:27:22 PM Viking Therapeutics Q1 Loss/share $0.07 Vs. Loss $0.10 Year Ago
4/11/2019 7:05:17 AM Viking Therapeutics Presents New Data From Phase 2 Study Of VK2809 In Patients With NAFLD And Elevated LDL-Cholesterol
4/4/2019 7:32:38 AM Viking Therapeutics To Present New Data From Phase 2 Study Of VK2809 In Patients With NAFLD And Elevated LDL-Cholesterol
3/29/2019 7:45:58 AM William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Outperform
3/14/2019 8:44:35 AM William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Outperform
3/13/2019 4:09:12 PM Viking Therapeutics Q4 Loss/share $0.07 Vs. Loss $0.14 Year Ago
11/12/2018 7:39:14 PM Viking Presents Results From Phase 2 Study Of VK2809 In Patients With NAFLD